Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities.
Aygun B, Wruck LM, Schultz WH, Mueller BU, Brown C, Luchtman-Jones L, Jackson S, Iyer R, Rogers ZR, Sarnaik S, Thompson AA, Gauger C, Helms RW, Ware RE; TCD With Transfusions Changing to Hydroxyurea (TWiTCH) Trial Investigators. Aygun B, et al. Am J Hematol. 2012 Apr;87(4):428-30. doi: 10.1002/ajh.23105. Epub 2012 Jan 9. Am J Hematol. 2012. PMID: 22231377 Free article. Clinical Trial. No abstract available.
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.
Wood JC, Pressel S, Rogers ZR, Odame I, Kwiatkowski JL, Lee MT, Owen WC, Cohen AR, St Pierre T, Heeney MM, Schultz WH, Davis BR, Ware RE; TWiTCH Investigators. Wood JC, et al. Among authors: odame i. Am J Hematol. 2015 Sep;90(9):806-10. doi: 10.1002/ajh.24089. Am J Hematol. 2015. PMID: 26087998 Free PMC article. Clinical Trial.
Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the REACH Trial.
McGann PT, Tshilolo L, Santos B, Tomlinson GA, Stuber S, Latham T, Aygun B, Obaro SK, Olupot-Olupot P, Williams TN, Odame I, Ware RE; REACH Investigators. McGann PT, et al. Among authors: odame i. Pediatr Blood Cancer. 2016 Jan;63(1):98-104. doi: 10.1002/pbc.25705. Epub 2015 Aug 14. Pediatr Blood Cancer. 2016. PMID: 26275071 Free PMC article.
End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.
Farrell AT, Panepinto J, Desai AA, Kassim AA, Lebensburger J, Walters MC, Bauer DE, Blaylark RM, DiMichele DM, Gladwin MT, Green NS, Hassell K, Kato GJ, Klings ES, Kohn DB, Krishnamurti L, Little J, Makani J, Malik P, McGann PT, Minniti C, Morris CR, Odame I, Oneal PA, Setse R, Sharma P, Shenoy S. Farrell AT, et al. Among authors: odame i. Blood Adv. 2019 Dec 10;3(23):4002-4020. doi: 10.1182/bloodadvances.2019000883. Blood Adv. 2019. PMID: 31809537 Free PMC article.
The Consortium on Newborn Screening in Africa for sickle cell disease: study rationale and methodology.
Green NS, Zapfel A, Nnodu OE, Franklin P, Tubman VN, Chirande L, Kiyaga C, Chunda-Liyoka C, Awuonda B, Ohene-Frempong K, Inusa BPD, Ware RE, Odame I, Ambrose EE, Dogara LG, Oron AP, Willett C, Thompson AA, Berliner N, Coetzer TL, Novelli EM. Green NS, et al. Among authors: odame i. Blood Adv. 2022 Dec 27;6(24):6187-6197. doi: 10.1182/bloodadvances.2022007698. Blood Adv. 2022. PMID: 36264096 Free PMC article.
89 results